PAPERZILLA
Crunching Academic Papers into Bite-sized Insights.
About
Sign Out
← Back to papers
Health Sciences › Medicine › Pharmacology
Honeybee venom and melittin suppress growth factor receptor activation in HER2-enriched and triple-negative breast cancer
★
★
★
★
☆
SHARE
Overview
Paper Summary
Conflicts of Interest
Identified Weaknesses
Rating Explanation
Good to know
Topic Hierarchy
File Information
Paper Summary
Paperzilla title
Bee Venom and Docetaxel: Tag-teaming Triple-Negative Breast Cancer!
Honeybee venom and its main component, melittin, show potent anticancer activity against triple-negative and HER2-enriched breast cancer cells by suppressing the activation of EGFR and HER2. Furthermore, melittin synergizes with docetaxel to enhance antitumor effects in an aggressive TNBC allograft model and reduces PD-L1 expression in tumors.
Possible Conflicts of Interest
None identified.
Identified Weaknesses
Allograft Model Limitations
The in vivo experiments were conducted using an allograft model, which may not fully represent the complexity of human TNBC. While the allograft model allows for assessment of immune response, it does not perfectly mimic the human tumor microenvironment, potentially impacting the translation of findings to clinical settings.
Limited in vivo subtype representation
While the study investigated the in vitro effects of melittin on different breast cancer subtypes, the in vivo experiments were limited to the T11 cell line, which represents only the claudin-low subtype of TNBC. The efficacy of the combination treatment with docetaxel and melittin might differ across other subtypes of TNBC and should be investigated further.
Lack of optimization of combination therapy
Although the study suggests synergistic effects between melittin and docetaxel, it does not explore the optimal drug ratio or scheduling for combination therapy. Understanding the pharmacokinetics and pharmacodynamics of the combination would be crucial for clinical translation.
Incomplete mechanistic understanding
The mechanism by which melittin inhibits RTK dimerization and phosphorylation is not fully elucidated. Further investigations into the specific molecular interactions are needed to understand the precise mechanism of action.
Rating Explanation
This study provides compelling evidence for the anticancer properties of honeybee venom and melittin, especially in aggressive breast cancer subtypes. The research demonstrates a novel mechanism of action involving the disruption of RTK signaling and highlights the potential of melittin in combination therapy with docetaxel. The in vivo results using an allograft model further strengthen the findings. However, some limitations, such as the use of only one TNBC subtype in the in vivo model and the lack of detailed mechanistic understanding regarding RTK inhibition, prevent a rating of 5.
Good to know
This is our free standard analysis. Paperzilla Pro fact-checks every citation, researches author backgrounds and funding sources, and uses advanced AI reasoning for more thorough insights.
Explore Pro →
Topic Hierarchy
File Information
Original Title:
Honeybee venom and melittin suppress growth factor receptor activation in HER2-enriched and triple-negative breast cancer
File Name:
s41698-020-00129-0.pdf
[download]
File Size:
4.80 MB
Uploaded:
July 14, 2025 at 10:40 AM
Privacy:
🌐 Public
© 2025 Paperzilla. All rights reserved.